Inhibitors of angiogenesis in therapy of ovarian cancers

The capacity to induce growth of blood vessels represents one of the phenotypic traits of neoplastic cells. Several preclinical studies prove that the inhibition of growth of peri-neoplastic blood vesssels leads to restricted growth of primary tumours and of metastases. Nevertheless, clinical studies indicate that angiogenesis inhibitors are not such effective drugs as might be expected on the basis of studies conducted on animals. In this article we would like to draw the readers' attention to divergencies between preclinical and clinical results, in particular to those related to ovarian cancers. In the treatment of ovarian cancers, angiogenesis inhibitors combined with other drugs may prove to represent a relatively effective therapeutic approach.

Angiogenesis; Angiogenesis inhibitors; Ovarian cancer

[1] Hanahan D., Weinberg R.A.: "The hallmark、of cancer". Cell, 2000, 100, 57.

[2] Gimbrone M.A. Jr., Leapman S.B., Cotran R.S., Folkman J.: "Tumor dormancy in vitro by prevention of neovascularization''. J. Exp. Med., 1972, 136, 261.

[3] Udagawa T., Fernandez A., Achilles E.G., Folkman J., D'Amato R.J.: "Persistence of microscoptic human cancer in mice: alternation in the angiogenic balance accompanies lo、s of tumor donnancy". FASEB J., 2002, 16, 1361.

[4] O'Reily M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M. et al.: "Angiostatin: a novel angiogenesis inhibitor that mediates the suppre…on of metastases by a Lewis lung carcinoma". Cell, 1994, 79, 315.

[5] O'Reily M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S. et al.: "Endostatin: an endogenous inhibitor of angiogenesis and tumor growth". Cell, 1997, 88, 277.

[6] Verheul H.M.W., Yoest E.E., Schlingemann R.O.: "Are tumours angiogenesis-dependent?". J. Pathol., 2004, 202, 5.

[7] Kerbel R.S.: "Tumor angiogenesis: past, present and the near future". Carcinogenesis, 2000, 21, 505.

[8] Longo R., Sarmiento R., Fanelli M., Capaccetti B., Gattuso D., Gasparini G.: "Anti-angiogenic therapy: rationale, challenges and clinical studies". Angiugene.Iis, 2002, 5, 237.

[9] Scappaticci F.A.: "Mechanisms and future directions for angiogenesis-based cancer therapies". J. Clin. Oncol., 2002, 20, 3906.

[10] Tonini T., Rossi F., Claudio P.P.: "Molecular basis of angiogenesis and cancer". Oncogene, 2003, 22, 6549.

[11] Dvorak H.F.:'Tumours: wounds that do not heal: similarities between tumor stroma generation and wound healing". N. Engl. J. Med., 1986, 315, 1650.

[12] Dvorak H.F.: "How tumors make bad blood vessels and stroma". Am. J. Pathol., 2003, 162, 1747.

[13] Hanahan D., Folkman J.: "Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis“ Cell,1996, 86, 353.

[14] Coomber B.L., Yu, J.L., Father、K.E.,Plumb C., Rak J.W.: "Angiogenesis and the role of epigenetics in metastasis". Clin. Exp Metastasis, 2003, 20, 215.

[15] Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J.: "Vascular - specific growth factors and blood vessel formation". Nature, 2000, 407, 242.

[16] Jain R.K., Duda D.G.: "Role of bone marrow-derived cells in tumor angiogenic and treatment". Cancer Cell, 2003, 3, 515.

[17] Hendrix M.J., Seftor E.A., Hess A.R.,Seftor R.E.B.: "Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma" Nature Rev., 2003, 3, 411.

[18] Sivridis E.,G iatromanolaki A.,K oukourakis M.I.: "The vascular network of tumours - what is it not for?". J. Pathol., 2003, 201, 173.

[19] Jain R.K.: "Barriers to drug delivery in solid tumor、“ Sci. Am., 1994, 271, 58.

[20] Kerbel R., Folkman J.: "Clinical translation of angiogenesis inh伽tors". Nature Rev., 2002, 2, 727.

[21] Kerbel R.S.: "Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results"． J. Clin. Oncol. 2001, 19, 45s.

[22] Davis D.W., McConkey D.J., Zhang W., Herbst R.S.: "Antiangiogenic tumor therapy". Biotechniques,2003, 34, 1048.

[23] Boehm T., Folkman J., Browder T., O'Reilly M.: "Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance". Nature, 1997, 390, 404.

[24] Browder T., Butterfield E., Kraling B.N., Shi B., Marshall B., O'Reilly M.S., Folkman J.: "Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer". Cancer Res., 2000, 60, 1878.

[25] Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D.J. et al.: "Continuous low-does therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity". J. Clin. Inv., 2000, 105, R 15

[26] Kuo C.J.,F arnebo F.,Y u E.Y., Christofferson R.,S wearing R.A.,C arter R. et al.: "Comparative evaluation of the anti tumor activity of antiangiogenic proteins delivered by gene transfer". Proc. Natl. Acad. Sci. USA, 2001, 98, 4605.

[27] Marshall E.: "Setbacks for endostatin". Science, 2002, 295, 2198.

[28] Millar A.W., Lynch K.P.: "Rethinking clinical trials for cytostatic drugs". Nature, 2003, 3, 540.

[29] Rothenberg M.L., Carbone D.P., Johnson D.H.: " Improving the evaluation of new cancer treatments: challenges and opportunities". Nature Rev., 2003, 3, 303.

[30] Eisen T., Boshoff C., Mak J, Sapunar F., Vaughan M.M., Pyle L. : "Continuous low dose thalidomide: a phase study in advanced melanoma, renal cell, ovarian and breast cancer". B1: J. Cancer, 2000, 82 (4), 812.

[31] Abramson N., Stokes P.K., Luke M., Marks A.R., Harris J.M.: "Ovarian and papillary- serous peritioneal carcinoma: pilot study with thalidomide". J Clin. Oncul., 2002, 20 (4), 1147.

[32] Eisen T.: "Thalidomide in solid malignancies". J. Clin. Oncol., 2002, 20 (11), 2607.

[33] Hurteau J.A., Blessing J.A., DeCe、are S.L., Cresman W.T.: "Evaluation of recombinant human interlekuin 12-in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study". Gynecol. Oncol., 2001, 82 (1), 7.

[34] Berlin J.,T utsch K.B.,A rzoomanian R.Z.,A lberti D.,B inger K.,F eierabend C.: "Phase I and phannacokinetic study of micronized formulation of carboxy-amidotriazole, a calcium signal transduction ihibitor: toxicity, bioavaibility and the effect of food". Clin Cancer Res., 2002, 8, 86.

[35] See H.T., Kavanagh J.J., Hu W, Bast R.C. Jr.: "Target therapy for epithelial ovarian cancer: Current status and future prospects". Int. J. Gynecol. Cancer., 2003, 13, 701.

[36] Schilder R.J., Kohn E., Sill M.E., Gewandowski G., Lee R.B., Decesare S.L.: "Phase II trial of gefitinib in patiens with recurrent ovarian or primary peritoneal cancer". Gynecology Oncology Group 170 C. Proceedings of the American Society of Clinical Oncology (abstract), 2002, 22, 451.

[37] Perrotte P., Matsumoto T., Inoue K., Kuniyasu H., Eve B.Y., Hicklin D.J. et al.: "Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transistional cell carcinoma growing orthotopically in nude mice". Clin. Cancer Res., 1999, 5, 257.

[38] Bhargava P., Marshall J.L., Dahut W., Rizvi N., Trocky N., Williams J.l. et al.: "A phase I and pharmacokinektics study of squalamine, a novel antyangiogenic agent, in pactiens with advanced cancers". Clin. Cancer. Res., 2001, 7, 3912.

[39] Li D., Willams J.l., Pietras R.J.: "Squalamine and cipsplatin block angiogenesis and growth of human ovarian cancer cell with or without HER-2 gene overexpression". Oncogene, 2002, 21, 2805.

[40] Swannie J.C., Kaye S.B.: "Protein kinase C inhibitors". Curr. Oneal. Rep., 2002, 437.

[41] Grace M., Youngster S., Gitlin G., Sydor W., Xie L., Westreich L. et al.: "Structural and biologic characterization of pegylated recombinant IFN-alpha2bg". J. Interferon Cytokine Res., 2001, 21, 1103.

[42] Miller K.D., Sweeney C.J., Sledge G.W. Jr.: "Redefining the target: chemotherapeutics as antiangiogenics". J. Clin. Oneal., 2001, 19, 1195.

[43] Yu J.L., Rak J.W, Coomber B.L., Hicklin D.J., Kerbel R.S.: "Effect on p53 status of tumor response to angiogenic therapy". Science, 2002, 295, 1526.

[44] Sonmezer M., Giingor M., Ensari A, Ortac: "Prognostic significance of tumor angiogensis in epithelial ovarian cancer : in ossociation with transforming growth factor b and vascular growth factor". Int. J. Gynecol Cancer, 2004, 14, 82.

[45] Dunfield L.D., Nachtigal M.W.: "Inhibition of the anti proliferative effect of T GF beta by EGF in primary human ovarian cancer". Oncogene, 2003, 22, 4745.